npj Parkinsons Disease

Papers
(The TQCC of npj Parkinsons Disease is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation322
Current and projected future economic burden of Parkinson’s disease in the U.S.264
Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens142
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside113
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease72
Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life62
Dynamic control of the dopamine transporter in neurotransmission and homeostasis59
Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management57
Incidence of Parkinson disease in North America57
Toward therapeutic electrophysiology: beta-band suppression as a biomarker in chronic local field potential recordings55
The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study55
How COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review54
Genetic and environmental factors in Alzheimer’s and Parkinson’s diseases and promising therapeutic intervention via fecal microbiota transplantation52
Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes50
Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease49
Multi-modality machine learning predicting Parkinson’s disease48
Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?47
Diagnostic value of skin RT-QuIC in Parkinson’s disease: a two-laboratory study46
Subthalamic and pallidal deep brain stimulation for Parkinson’s disease—meta-analysis of outcomes46
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies45
Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity45
A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson’s disease45
A systematic review on exercise and training-based interventions for freezing of gait in Parkinson’s disease44
Probiotics synergized with conventional regimen in managing Parkinson’s disease43
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease43
Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson’s disease42
Mechanisms of peripheral levodopa resistance in Parkinson’s disease39
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology37
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients37
Stress and mindfulness in Parkinson’s disease – a survey in 5000 patients35
Eight-hours conventional versus adaptive deep brain stimulation of the subthalamic nucleus in Parkinson’s disease34
Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis33
Oleh Hornykiewicz, a giant in the understanding and treatment of Parkinson disease33
Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson’s disease32
Fine mapping of the HLA locus in Parkinson’s disease in Europeans32
The role of brain perivascular space burden in early-stage Parkinson’s disease31
Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease31
Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI30
Diurnal modulation of subthalamic beta oscillatory power in Parkinson’s disease patients during deep brain stimulation30
Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations30
Early constipation predicts faster dementia onset in Parkinson’s disease30
Rheumatoid arthritis decreases risk for Parkinson’s disease: a Mendelian randomization study29
Cofilin 1 promotes the pathogenicity and transmission of pathological α-synuclein in mouse models of Parkinson’s disease29
A transcriptome-wide association study identifies susceptibility genes for Parkinson’s disease29
Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation29
Cognitive function in people with and without freezing of gait in Parkinson’s disease29
Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study28
Lewy body disease or diseases with Lewy bodies?28
Specific immune status in Parkinson’s disease at different ages of onset28
Subthalamic beta bursts correlate with dopamine-dependent motor symptoms in 106 Parkinson’s patients27
A real-world study of wearable sensors in Parkinson’s disease27
Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease27
Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson’s disease27
Effects of the agility boot camp with cognitive challenge (ABC-C) exercise program for Parkinson’s disease26
Mining genetic and transcriptomic data using machine learning approaches in Parkinson’s disease26
Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson’s disease26
A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population26
Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease26
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei26
Repetitive transcranial magnetic stimulation improves Parkinson’s freezing of gait via normalizing brain connectivity25
Multivariate prediction of dementia in Parkinson’s disease25
Prognostic biomarkers of Parkinson’s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach24
Multiple comorbid sleep disorders adversely affect quality of life in Parkinson’s disease patients24
Speech-based characterization of dopamine replacement therapy in people with Parkinson’s disease24
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease24
Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson’s disease24
Gender gap in deep brain stimulation for Parkinson’s disease24
Nitrosative stress in Parkinson’s disease23
Multimodal phenotypic axes of Parkinson’s disease23
α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission23
Parkinson’s disease clinical milestones and mortality23
A systematic review and meta-analysis on effects of aerobic exercise in people with Parkinson’s disease22
“Hot cross bun” is a potential imaging marker for the severity of cerebellar ataxia in MSA-C22
RETRACTED ARTICLE: Non-invasive vagus nerve stimulation improves clinical and molecular biomarkers of Parkinson’s disease in patients with freezing of gait22
Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor22
Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins22
Effect of Parkinson’s disease and two therapeutic interventions on muscle activity during walking: a systematic review22
Reference SVA insertion polymorphisms are associated with Parkinson’s Disease progression and differential gene expression22
Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson’s disease patients22
Thalamic morphology predicts the onset of freezing of gait in Parkinson’s disease21
A systematic review and meta-analysis of inflammatory biomarkers in Parkinson’s disease21
Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors21
Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology21
Irritable bowel syndrome and Parkinson’s disease risk: register-based studies21
A blinded, controlled trial of objective measurement in Parkinson’s disease21
Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures20
Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI20
A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease20
Oral and gut dysbiosis leads to functional alterations in Parkinson’s disease20
Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM2020
Post-GWAS knowledge gap: the how, where, and when19
The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease19
A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson’s disease19
Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson’s disease19
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease19
Insights into the multifaceted role of circular RNAs: implications for Parkinson’s disease pathogenesis and diagnosis19
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease19
High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy18
Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages18
Balance response to levodopa predicts balance improvement after bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease18
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation18
Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes17
A proteogenomic view of Parkinson’s disease causality and heterogeneity17
Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America17
DAT and TH expression marks human Parkinson’s disease in peripheral immune cells17
Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson’s disease17
Exploring human-genome gut-microbiome interaction in Parkinson’s disease17
Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity17
Imaging mass cytometry reveals generalised deficiency in OXPHOS complexes in Parkinson’s disease16
Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts16
Mitophagy and reactive oxygen species interplay in Parkinson’s disease16
Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons16
α-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability16
Exosome markers of LRRK2 kinase inhibition16
Akinetic rigid symptoms are associated with decline in a cortical motor network in Parkinson’s disease16
Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease16
Perspective on the current state of the LRRK2 field16
Comparative proteomic analysis highlights metabolic dysfunction in α-synucleinopathy16
Probable REM sleep behavior disorder is associated with longitudinal cortical thinning in Parkinson’s disease15
Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease15
Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease15
Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US15
A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson’s disease15
Parkinson’s disease-associated, sex-specific changes in DNA methylation at PARK7 (DJ-1), SLC17A6 (VGLUT2), PTPRN2 (IA-2β), and NR4A2 (NURR1) in cortical neurons15
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting15
A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD15
Long-term Parkinson’s disease quality of life after staged DBS: STN vs GPi and first vs second lead15
Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson’s disease15
The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters15
Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease15
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study15
Predictors of clinically significant quality of life impairment in Parkinson’s disease15
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia15
Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool14
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase14
A series of helical α-synuclein fibril polymorphs are populated in the presence of lipid vesicles14
Serum lipid profile among sporadic and familial forms of Parkinson’s disease14
Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population14
Specific gut microbiota alterations in essential tremor and its difference from Parkinson’s disease14
Arm swing responsiveness to dopaminergic medication in Parkinson’s disease depends on task complexity14
Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity14
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease14
Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration14
A comparative study of asleep and awake deep brain stimulation robot-assisted surgery for Parkinson’s disease14
Biallelic expansion in RFC1 as a rare cause of Parkinson’s disease14
Adverse effects of hypertension, supine hypertension, and perivascular space on cognition and motor function in PD14
Combining skin and olfactory α-synuclein seed amplification assays (SAA)—towards biomarker-driven phenotyping in synucleinopathies14
Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias14
Parkinson’s disease patients benefit from bicycling - a systematic review and meta-analysis14
Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease14
0.07030987739563